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1892RESULTS: After 8 months, 22 of 50 children (44%) on OIT and
1 of 21 (4.8%) on egg avoidance were desensitized to the target
dose, 23 of 50 (46%) were partially desensitized (dose <1 g), and
5 of 50 (10%) discontinued. IgG4 concentrations to Gal d 1-4
and IgA to Gal d 1-2 increased significantly, whereas IgE to Gal
d 2 decreased. A heatmap analysis of the IgE patterns revealed 3
distinct clusters linked with the clinical outcome. High baseline
egg whiteespecific IgE and polysensitization to Gal d 1-4 related
with failure to achieve the maintenance dose at 8 months. After
18 months of treatment, 36 of 50 patients (72%) were desensi-
tized and 8 of 50 (16%) partially desensitized.
CONCLUSIONS: OIT with raw egg enables liberation of egg
products into the daily diet in most patients. Subjects with high
egg whiteespecific IgE concentrations and sensitization to
multiple egg allergen components at baseline benefit from pro-
longed treatment.  2021 The Authors. Published by Elsevier
Inc. on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/). (J Allergy
Clin Immunol Pract 2021;9:1892-901)
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INTRODUCTION
Oral tolerance is the normal physiologic response to ingested
food proteins, and a breakdown in this process leads to sensiti-
zation and the development of food allergy.1 The prevalence of
food allergy ranges from 3% to 8% in children and seems to be
increasing.2 Hen’s egg allergy is the second most common food
allergy in young children, with an estimated prevalence of 0.5%
to 2.5%.2 Although most food allergies are transient and resolve
by school age, egg allergy may persist until adulthood.3,4
Persistent food allergy is associated with a more severe clinical
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DBPCFC- Double-blind, placebo-controlled food challenge
EW-IgE- Egg whiteespecific IgEIQR- Interquartile range
OIT- Oral immunotherapycourse and high specific IgE levels with sensitization to food
allergens resistant to heat and enzymatic digestion, and thus,
reactivity to the food in the processed or heated form.3
The current standard of care for food allergy is avoidance of
the offending food and administration of emergency medication
on accidental exposure.4 Food avoidance and unpredictable re-
actions related to accidental exposures decrease the quality of life
of the patients and their families.4 There is, therefore, an unmet
need to develop effective therapies for the treatment of food
allergy.
Oral immunotherapy (OIT) is an experimental, therapeutic
approach in which gradually increasing doses of food allergens
are administered orally.5 OIT can desensitize up to 80% of
children with persistent food allergy, and in a subset lead to long-
term immune tolerance.6 Desensitization is a state of temporary
antigen hyporesponsiveness that depends on regular food intake.
If dosing is interrupted, the protective effect is lost.7 Moreover,
cofactors, such as physical exercise and infections, may lower the
threshold of reactivity and trigger reactions to a previously
tolerated dose.8 The ultimate goal is to develop long-lasting
immune tolerance, which is defined as the ability to ingest the
food without symptoms regardless of irregular consumption or
periods of avoidance. Many studies prefer the term “sustained
unresponsiveness,” because there is no consensus on the length of
the avoidance needed to define permanent tolerance.5 OIT
inducing successful desensitization has been reported to cow’s
milk, hen’s egg, wheat, and peanut.6 OIT uses the pathways
underlying oral tolerance, that is, the physiologic tolerogenic
response upon oral administration of food proteins.1 Current
evidence suggests that OIT can desensitize more than 80% of
children with egg allergy,9 and elicit long-term tolerance in 50%
after 4 years of treatment.10,11 The mechanisms behind desen-
sitization and possible long-term effects remain under active
investigation.7 Open questions remain regarding optimal
desensitization and maintenance protocols, safety, and selection
of patients benefiting from OIT.
We aimed to determine the efficacy of an 8-month egg OIT
protocol with raw, pasteurized egg white powder and study its
effects on humoral immune responses in children with persistent
egg allergy. The maintenance dose was 1 g of egg white protein,
which corresponds to approximately one-third of the protein
content of an egg white (3 g).
METHODS
This was a randomized, open, trial investigating the efficacy and
immunologic effects of hen’s egg OIT in children. The key study
outcome was the proportion of participants desensitized after 8
months of OIT. Secondary outcomes were (1) the proportion of
participants partially desensitized after 8 months of OIT, (2) the
proportion of participants desensitized after 18 months of OIT, (3)
the proportion of participants partially desensitized after 18 months
of OIT, (4) the proportion of participants able to consume 1.5 g of
heated egg protein after 3 months of maintenance therapy, and (5)changes in Gal d 1-4especific IgE, IgA, and IgG4 antibody levels
and their correlation to the tolerated egg dose after 0 and 8 months
of OIT.
Desensitization was defined as the ability to consume 1 g of egg
white protein without symptoms and partial desensitization as the
ability to consume any dose below 1 g of egg white protein without
symptoms.
Study population
The study included 50 children and adolescents, aged 6 to 17
years, referred to the Department of Allergology, Helsinki University
Central Hospital, Finland, for evaluation of hen’s egg allergy. The
participants were recruited between June 2013 and September 2017.
The Helsinki University Hospital of Children and Adolescents
Ethics Committee approved the study, and each participant older
than 6 years as well as his or her guardian gave written informed
consent.
Seventy-six patients underwent double-blind, placebo-controlled
food challenges (DBPCFCs) with heated egg white, performed as
previously described.12 The challenges were interpreted positive and
dosing was stopped in line with the PRACTALL consensus
criteria.13 We used a modified threshold-adjusted score to evaluate
reaction severity: 1 to 5 indicated mild, 6 to 13 moderate, and 14 to
23 severe reactions.12,14 The inclusion criteria for the study were age
6 to 17 years, a clinical history of hen’s egg allergy, sensitization to
egg white (egg whiteespecific IgE [EW-IgE] 0.35 kU/L), and a
moderate to severe reaction in the baseline DBPCFC to heated egg
white. Subjects were excluded for any of the following reasons: poor
adherence, uncontrolled or severe asthma, severe systemic illness,
active autoimmune disease, malignant neoplasia, or pregnancy.15
The study subjects were randomized 3:2 to egg OIT or
avoidance. The avoidance group underwent an open oral egg
rechallenge after 6 months and crossed over to OIT after 8 months
(Figure 1, A).
Oral immunotherapy
The OIT protocol is presented in Table E1 in this article’s Online
Repository at www.jaci-inpractice.org. OIT was carried out with
pasteurized, spray-dried, raw egg white powder (Dava Foods, Piis-
panristi, Finland) with daily dosing at home. The first dose and
escalations to 1, 4, 25, and 350 mg were taken at the outpatient
clinic. The dose was increased weekly for the first 3 weeks and from
then on biweekly. The build-up phase lasted for 8 months. The
target maintenance dose was 1 g of egg white protein, corresponding
approximately to one-third of the protein content of an egg white. In
the maintenance phase, the participants consumed a total amount of
one-third of an egg white daily: raw egg white powder at least 3
times a week and boiled or fried egg or foods containing heated egg
on the remaining days. Egg yolk and different degrees of heating
were allowed. The participants who were unable to ingest 1 g at 8
months continued updosing with raw egg powder, and in the case of
continuous dosing symptoms, they switched to heated egg. After 3
months of maintenance therapy on the target dose, an open oral egg
challenge with 1.5 g of heated egg protein, corresponding to one-half
of a boiled egg white, was performed. If passed, the patients were
allowed to consume up to one-half of an egg in the heated or one-
third in the raw form. Daily consumption was continued. They were
advised to incorporate heated egg products (eg, meatballs, pasta,
bread, pancakes, and pastries) into their daily diet and liberate di-
etary restrictions of heated egg at home and in the school diet.
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FIGURE 1. (A) Study enrollment and randomization and (B) OIToutcome in 50 patients.
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Previous OIT, n (%) 7 (14)
Milk 5 (10)
Milk and wheat 2 (4)
Asthma, n (%) 30 (60)
Persistent 21 (42)
Intermittent 9 (18)
Allergic rhinitis, n (%) 39 (78)
Atopic dermatitis, n (%) 37 (74)
Baseline DBPCFC, n (%)
Moderate 41 (82)
Severe 9 (18)
FIGURE 2. Hen’s egg OIToutcome at 8 and 18 months. HE, Hen’s
egg.
J ALLERGY CLIN IMMUNOL PRACT
VOLUME 9, NUMBER 5
PALOSUO ETAL 1895A standard dose of antihistamine was taken daily at least 1 hour
before the egg dose to reduce possible dose-related oropharyngeal
symptoms.15 Dosing symptom severity was assessed by the CoFAR
Grading System for Allergic Reactions.10 Mild to moderate dosing
symptoms were treated with an additional antihistamine dose and
with oral prednisolone if the symptoms persisted for more than 30
minutes. For treatment of severe systemic reactions, the patients had
an adrenaline autoinjector. In the case of mild dosing symptoms, the
patient continued with the same dose until resolution of symptoms
before dose escalation. If the symptoms were moderate or severe, the
patient reduced dosing to the previously tolerated dose, after which
dose escalation was adjusted individually. Physical exercise was
forbidden 1 hour before and after each dose, and on days of esca-
lation. The dose was not escalated in the case of an infectious
disease.Blood samples and immunologic parameters
Venous blood samples were collected before OIT and avoidance,
and after 3 and 8 months of OIT. Serum and plasma were sepa-
rated, aliquoted, and stored at 20C. EW-IgE, serum IgE, and
plasma IgA and IgG4 antibody concentrations to Gal d 1 (ovo-
mucoid), Gal d 2 (ovalbumin), Gal d 3 (conalbumin), and Gal d 4
(lysozyme) were measured by ImmunoCAP (Thermo Fisher,
Uppsala, Sweden).Statistics, correlations, and hierarchical clustering
For analysis of data, we used Graph Pad Prism 8 for Windows
(GraphPad Software, Inc, La Jolla, Calif). The antibody data were
expressed as medians with 95% CI, and differences between medians
were analyzed with the Student t test with a 2-tailed test of signif-
icance. The Mann-Whitney U test or the Kruskal-Wallis test was
used when variances were different between groups for unpaired
comparisons. The association between clinical parameters, antibody
concentrations, and the OIT dose was examined by Spearman Rank
and Pearson correlation tests. Differences at P less than .05 were
considered statistically significant. K-meansebased hierarchical
clustering was carried out with Perseus omics analysis and visuali-
zation software.16
RESULTS
The study enrollment is shown in Figure 1, A. Of the 76
patients who underwent DBPCFC, 59 were eligible for the
study. Fifty-six patients were randomized: 33 to start OIT and
23 to continue avoidance. Five withdrew and 1 rechallenge was
negative. Altogether 50 patients started the OIT protocol
(Table E1; Figure 1, B). The baseline characteristics of these 50
patients are presented in Table I.
Desensitization
In the baseline DBPCFC, the median (interquartile range
[IQR]) heated egg white protein dose successfully consumed
without symptoms was 5 (5-50) mg. One (4.8%) of the 21
controls passed the rechallenge after 6 months. In the remaining
20 patients, the rechallenge was positive with no significant
difference in the successfully consumed dose compared with the
baseline challenge. After 8 months of OIT, 22 of 50 patients
(44%) reached the maintenance dose of 1 g of raw egg protein
(desensitized) and 23 of 50 (46%) a dose less than 1 g (partially
desensitized), with a median (IQR) dose of 300 (175-700) mg
and a range of 20 to 700 mg. Five patients (10%) discontinued
during the build-up phase, 4 because of continuous gastroin-
testinal dosing symptoms and 1 because of nonadherence
(Figure 1, B). The median (IQR) successfully consumed dose
increased from 5 (5-50) mg of heated egg protein to 700 (175-
1000) mg of raw egg protein (P < .0001.)
During the build-up phase, 41 of 50 patients (82%) experi-
enced dosing symptoms. Gastrointestinal symptoms (abdominal
FIGURE 3. Antibody responses at6, 0, 3, and 8 months of OIT. Concentrations of Gal d 1-4especific IgG4, IgA, and IgE antibodies were
measured by ImmunoCAP. Results are expressed as medians with 95% CI. Significance is indicated by *P <.05, **P <.01, ***P <.001,
****P < .0001 by Mann-Whitney t test.
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oral pruritus in 12 of 50 (24%), and skin symptoms (erythema,
urticaria, flare-up of eczema) in 3 of 50 patients (6%). No res-
piratory symptoms, severe reactions requiring adrenaline, or
anaphylaxes17 were observed. Of the 23 of 50 patients partially
desensitized at 8 months, 22 of 23 continued updosing and 1
withdrew because of dosing symptoms (Figure 1, B). At this
point, 8 of 22 switched to heated egg because of dosing symp-
toms caused by raw egg but tolerated egg that had been heated
for at least 10 minutes (boiled egg or egg-containing foods). After
18 months of OIT, 14 of 22 of the partially desensitized subjects
reached the target dose of 1 g and 8 of 22 continued regular egg
consumption at a median (IQR) maintenance dose of 350 (350-
550) mg and a range of 100 to 700 mg. After 18 months of OIT,
altogether 44 of 50 patients (88%) were consuming egg; 36 of 50
(72%) were considered desensitized and 8 of 50 (16%) partially
desensitized (Figure 2). More than half the patients, that is, 27 of50 (54%), had liberated dietary restrictions of egg at home and in
the school diet.
To assess tolerance to heated egg, a post-OIT open oral egg
challenge with one-half of a cooked egg white, corresponding to
1.5 g of protein, was performed to the 36 fully desensitized
patients who reached the target dose of 1 g egg protein. All 36
passed the challenge after 3 months of maintenance therapy on
the target dose.
Changes in concentrations of Gal d 1-4especific
IgE, IgG4, and IgA during OIT
Serum IgE and plasma IgA and IgG4 levels to Gal d 1 (ovo-
mucoid), Gal d 2 (ovalbumin), Gal d 3 (conalbumin), and Gal
d 4 (lysozyme) and EW-IgE were measured at different time
points: at the beginning of the avoidance period (6 m) or OIT
(0 m), and after 3 months (3 m) and 8 months (8 m) of OIT
(Figure 3).
TABLE II. Baseline EW-IgE and Gal d 1-4especific IgE levels in the











Egg white IgE (kU/L)*
Median 9.8 53 137
Mean 21.6 197 246
Gal d 1 IgE (kU/L)*
Median 8.2 36 39.3
Egg white IgE (kU/L)*
Mean 21.9 73.4 92.2
Gal d 2 IgE (kU/L)*
Median 4.8 34.1 39.1
Mean 8.8 127 185
Gal d 3 IgE (kU/L)*
Median 0.18 6.42 29.5
Mean 1.77 83.8 54.7
Gal d 4 IgE (kU/L)†
Median 0.71 2.61 19.6
Mean 2.28 23.7 33.0
Polysensitization to
Gal d 1-4, n (%)
No. of patients 6 (27) 16 (70) 5 (100)
The median and mean IgE levels differed significantly between the subjects
desensitized at 8 mo compared with the partially desensitized or failed subjects.
Polysensitization to all 4 allergens was frequent in the partially desensitized and
failed groups.
*P < .005, Kruskal-Wallis test.
†P < .01, Kruskal-Wallis test.
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showed no statistically significant differences between the
beginning of avoidance (6 m) and OIT (0 m) except for
increased IgA to Gal d 3. This is probably explained by technical
variation in the measurements because IgA concentrations at all
time points were close to or below the detection level. The
concentration of IgG4 antibodies to Gal d 1-4 and IgA antibodies
to Gal d 1 and 2 increased linearly and significantly throughout
the OIT period (P < .001). The concentration of IgE to Gal d 1-
4 increased during the first 3 months followed by a decrease at 8
months, but the decrease was significant only for Gal d 2 (P <
.01) (Figure 3).Correlation of clinical characteristics and antibody
levels with OIT clinical outcome
There was a moderate correlation between the tolerated and
cumulative DBPCFC doses (r ¼ 0.53 and 0.56, respectively) and
the OIT dose at 8 months (P < .0001). Age, reaction severity, or
the presence of comorbidities did not associate with the OIT
outcome. The baseline median and mean EW-IgE and Gal d 1-
4especific IgE levels differed significantly in the subjects
desensitized at 8 months compared with the partially desensitized
or failed subjects (Table II). Because of large variability, we could
not determine threshold IgE levels predictive of desensitization.
However, 21 of 22 (95%) subjects desensitized at 8 months had
IgE levels below 57 kU/L for egg white, 44 kU/L for Gal d 1,
and 30 kU/L for Gal d 2 at baseline. Approximately half, that is,12 of 23 (48%), of the partially desensitized subjects had baseline
IgE levels below these cutoffs.
Gal d 1-4especific IgE concentrations correlated at all time
points (apart from Gal d 4 at 8 months) inversely with the
tolerated egg dose at 8 months of OIT (r ¼ 0.51 to 0.61; P
< .0001). Similarly, IgA antibody concentrations to Gal d 1 and
Gal d 2 at 8 months correlated inversely with the tolerated egg
dose at 8 months. Figure 4 shows the correlation of the OIT dose
at 8 months with Gal d 1e and Gal d 2especific IgE (loga-
rithmic) concentrations at 0 month and IgA (logarithmic) con-
centrations at 8 months.
A heatmap analysis of the logarithmic (log10) IgE concentra-
tions at all time points, based on the egg dose tolerated at 8
months, formed 3 distinct clusters (Figure 5, A). Cluster 1
(bottom) includes subjects with the highest log-transformed IgE
concentrations (mean, 2.02  0.60) to Gal d 1-4 throughout the
OIT period. None of the patients in this cluster were fully
desensitized at 8 months. Cluster 2 (middle) includes the sub-
jects with the lowest Gal d 1-4especific IgE concentrations
(mean, 0.14  0.96) throughout the OIT period. Of these
patients, 71% (15 of 21) were fully desensitized by 8 months.
Cluster 3 (top) includes polysensitized patients with intermediate
IgE concentrations (mean, 0.85  0.70) to Gal d 1-4; in this
cluster, 39% (7 of 18) were desensitized after 8 months of OIT.
Some patients showed increased production of IgA and IgG4
mostly to Gal d 2 at 3 and 8 months, but associations of clusters
and the OIT dose were not formed (Figure 5, B and C).
At baseline, 54% (27 of 50) of the subjects were sensitized to
all 4 allergen molecules Gal d 1-4 (Table II). This poly-
sensitization correlated significantly with the dose tolerated at 8
months (r ¼ 0.477; P < .001) and was associated with OIT
discontinuation and failure to achieve the maintenance dose of 1
g. All 5 OIT failures and 70% (16 of 23) of the partially
desensitized patients were polysensitized to Gal d 1-4, whereas
only 22% (6 of 27) of the polysensitized patients were fully
desensitized at 8 months.DISCUSSION
We describe an effective hen’s egg OIT protocol using raw,
pasteurized egg white powder in 50 children with moderate to
severe allergic reactions to heated egg diagnosed by DBPCFC. In
line with previous studies, allergen-specific IgE levels increased
slightly during the first 3 months followed by a decrease at 8
months, whereas allergen-specific IgA and IgG4 antibodies
gradually increased throughout the OIT build-up phase. A
heatmap analysis of the antibody responses revealed distinct
clusters linked to the clinical outcome. High baseline EW-IgE
and especially polysensitization to Gal d 1-4 related with OIT
discontinuation and failure to achieve the maintenance dose at 8
months. However, after 18 months of OIT, up to 88% were
consuming egg. Most children were able to incorporate egg
products into their daily diet and more than half were able to
liberate dietary restrictions at home and in the school diet.
Hen’s egg allergy resolves spontaneously in most children,18
and approximately 70% of children reacting to raw egg tolerate
baked egg.19 The most important egg allergen, Gal d 1 (ovo-
mucoid), retains its allergenicity even after extensive heating and
is stable against enzymatic digestion, in contrast to the unstable
egg allergens Gal d 2 (ovalbumin), Gal d 3 (conalbumin), and
Gal d 4 (lysozyme). Sensitization to Gal d 1 and its sequential
FIGURE 4. Pearson correlation of the OIT dose at 8 months to Gal d 1e and Gal d 2especific IgE and IgA antibody (logarithmic) con-
centrations after 0 and 8 months of OIT.
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persistent egg allergy.12,20,21 An inclusion criterion for our study
was a moderate to severe reaction to heated egg in DBPCFC.
Consequently, children with mild symptoms or allergy to raw
egg only were excluded. In the OIT build-up phase, we used raw
egg white to ensure optimal desensitization to all egg allergens. In
the maintenance phase, the children were advised to consume
both raw and heated egg to maintain successful desensitization.During the OIT build-up phase, 82% of the children expe-
rienced dosing symptoms, mainly mild to moderate gastroin-
testinal symptoms. No severe reactions were seen. In the case of
continuous symptoms, we adjusted the protocol individually by
returning to a dose tolerated without symptoms and delayed dose
escalation. These children benefited from a longer build-up phase
with individually adjusted, slower dose increments. After 18
months of OIT, 60% of these partially desensitized subjects were
FIGURE 5. Hierarchical Euclidean clustering of the OIT dose at 8 months (y-axis) in relation to logarithmic (log10) allergen-specific (A) IgE,
(B) IgA (B), and (C) IgG4 antibody concentrations at 0, 3, and 8 months. Each row represents 1 patient, and each column the log-
transformed antibody concentrations, with blue color for the lowest and red for the highest log10 concentrations. Gray is NA. NA, Not
applicable/available.
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symptoms from raw egg powder tolerated the equivalent dose in
the heated form, although they reacted to heated egg in the
baseline DBPCFC. These children were able to continue
updosing with heated egg without symptoms. Our results are
consistent with previous studies suggesting that continued
allergen administration over a prolonged period improves
desensitization rates and promotes a shift toward long-lasting
tolerance.11,22 We did not discontinue egg ingestion to eval-
uate sustained unresponsiveness, so we could not distinguish
patients with long-lasting tolerance from those with transient
desensitization.
In accordance with previous studies, OIT failure correlated
with high baseline EW-IgE levels.1,23,24 In 95% of the success-
fully desensitized subjects, the baseline IgE levels were below 57
kU/L for egg white, 44 kU/L for Gal d 1, and 30 kU/L for Gal
d 2. The higher the IgE concentrations of Gal d 1 and Gal d 2
were at baseline, the lower was the tolerated egg dose at 8
months. Our study showed for the first time that polysensitiza-
tion to all 4 egg allergen molecules Gal d 1-4 is associated with
poor desensitization responses. In an Australian HealthNuts
cohort,21 sensitization to multiple egg white allergens (Gal d 1, 2,
3) and egg yolk Gal d 5 at the age of 12 months increased the
risk of persistent egg allergy 4-fold at the age of 4 years, whereas
93% of children sensitized to only 1 egg allergen outgrew their
allergy. This suggests that IgE epitope diversity plays animportant role both in natural tolerance formation and in
desensitization induced by OIT. Most of our patients with high
baseline EW-IgE and sensitization to multiple egg allergens were,
nevertheless, able to achieve at least partial desensitization, but
they required individually adjusted prolonged treatment. These
partially desensitized patients continued regular ingestion of a
smaller egg portion, which was beneficial in protecting them
from unpredictable reactions related to accidental egg exposures.
IgA antibody concentrations to all studied allergens were very
low in all patients. Concentrations of IgA to Gal d 1 and 2
increased significantly at 8 months, predominantly in the group
of partially desensitized patients. Wright et al,24 on the contrary,
demonstrated increases in egg whiteespecific IgA in subjects
with sustained unresponsiveness evaluated after 2 to 4 years of
therapy. Our IgA measurements were from an earlier time point
in OIT and only to the specific allergen molecules, which might
explain the difference. Our data suggest, however, that patients
with elevated allergen-specific IgE at baseline and increased IgA
production during the OIT build-up phase may benefit from
prolonged and individually adjusted OIT. IgG4 antibodies
increased in all patients throughout the OIT build-up phase, but
neither this IgG4 increase nor the modest decrease in IgE anti-
bodies associated with the clinical outcome of OIT.
The efficacy of egg OIT in our study was similar to previously
published studies. Comparisons are, though, difficult to perform,
because the studies are methodologically very heterogeneous
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up protocols, duration of OIT, target doses, and maintenance
dosing.10,23,25-29 The first randomized trial on egg OIT was
published in 2012 by Burks et al10 with desensitization rates
comparable to our study. In this placebo-controlled, multicenter
study, 55% of 40 egg-allergic children aged 5 to 11 years were
desensitized after 10 months, and 75% after 22 months of OIT
with raw egg powder. Sustained unresponsiveness, evaluated by
passing an oral food challenge after discontinuing egg intake, was
seen in 28% after 2 years and in 50% after 4 years of OIT.11 The
largest randomized study so far is a multicenter study from Spain
including 101 children, aged 6 to 9 years, receiving OIT with
pasteurized raw egg white.30 They also included 16 children
tolerant to heated egg. The desensitization rate was 84% after 1
year of egg OIT, compared with 16% in children on an egg-free
diet. A daily 5% dose increment pattern seemed more efficient
than weekly dose escalations. A systematic Cochrane review on
egg OIT9 including 10 randomized trials summarized that 82%
of 249 egg-allergic children receiving OIT were desensitized,
defined as being able to consume a partial egg serving (1-7.5 g),
and 45% were able to consume a full serving, compared with
10% of 190 control children. All studies reported mild to severe
adverse effects, seen in altogether 75% of children receiving OIT
compared with 6.8% in the control group. All studies used
different methods and the sample sizes were small, which de-
creases the quality of the evidence.
There are several limitations to our study. This was not a
randomized controlled trial, and we had no placebo group. The
design was open-label and only the avoidance group crossed
over to OIT after 8 months. The rechallenge was performed
after 6 months of avoidance as an open food challenge, which
may have caused misclassification bias in the challenge
outcome. Some children could have outgrown their allergy
during the 2 months before starting OIT, although they were
above the typical age of natural egg allergy resolution. Safety
assessment was not included as a study outcome, which is a
clear limitation. We monitored dosing symptoms by a ques-
tionnaire filled during each visit instead of a daily diary, which
may have underestimated the occurrence of dosing symptoms.
Unfortunately, we did not collect blood samples for antibody
analysis at 18 months.
CONCLUSIONS
Our study shows that OIT with raw egg enables liberation of
egg products into the daily diet of most children with persistent
allergy to heated egg. Clustering of the protein-specific antibody
responses by heatmap analysis reveals different clinical patterns
that may help in designing the clinical treatment protocol. High
baseline EW-IgE and polysensitization to Gal d 1-4 relate with
discontinuation and the need for individually adjusted, pro-
longed treatment protocols.
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1901.e1 PALOSUO ETALONLINE REPOSITORYTABLE E1. Hen’s egg OIT build-up phase protocol and timing of
venous blood samples
Product Week Dose Dose (mg protein)
Blood
samples
Egg white powder 1 mg
/mL solution
1 0.1 mL 0.1 mg* 0 mo
2 0.2 mL 0.2 mg
3 0.4 mL 0.4 mg
4 1 mL 1 mg*
6 2 mL 2 mg
Egg white powder 10 mg/
mL solution
8 0.4 mL 4 mg
10 0.8 mL 8 mg
12 1.2 mL 12 mg
14 2.5 mL 25 mg* 3 mo
16 5 mL 50 mg
18 10 mL 100 mg
20 20 mL 200 mg
Egg white powder 22 3 g 350 mg*
24 6 g 700 mg
26 12 g 1 g
32 12 g 1 g 8 mo
The protocol for OIT consisted of an 8-mo build-up phase and a maintenance phase.
During the build-up phase, the participants ingested a daily dose of spray-dried,
pasteurized egg white powder dissolved in water (1 and 10 mg/mL solutions) and
after reaching the 350-mg dose, the powder was taken as such. The dose was
increased weekly for the first 3 weeks and from then on biweekly according to the
protocol above. The maintenance dose (1 g egg white protein) corresponded
approximately to one-third of an egg white. Antihistamine premedication was taken
daily at least 1 h before the OIT dose and was discontinued 2 wk after reaching the
maintenance dose. During the maintenance phase, the participants ingested a total
amount of one-third of an egg white daily: raw egg white powder at least 3 times a
week and boiled or fried egg or foods containing heated egg on the remaining days.
*Dose taken at the outpatient clinic.
